Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
TIL

TIL - Instil Bio, Inc. Stock Price, Fair Value and News

$8.26-0.49 (-5.60%)
Market Closed

61/100

TIL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

61/100

TIL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

TIL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TIL Price Action

Last 7 days

-6.9%

Last 30 days

6.3%

Last 90 days

-23.8%

Trailing 12 Months

-56.7%

TIL RSI Chart

TIL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TIL Valuation

Market Cap

56.0M

Price/Earnings (Trailing)

-0.75

Price/Sales (Trailing)

6.93

EV/EBITDA

-0.59

Price/Free Cashflow

-1.4

TIL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

TIL Fundamentals

TIL Revenue

Revenue (TTM)

8.1M

Rev. Growth (Yr)

35.55%

TIL Earnings

Earnings (TTM)

-75.1M

Earnings Growth (Yr)

40.98%

Earnings Growth (Qtr)

36.49%

TIL Profitability

EBT Margin

-1932.25%

Return on Equity

-62.34%

Return on Assets

-35.45%

Free Cashflow Yield

-71.59%

TIL Investor Care

Shares Dilution (1Y)

3.92%

Diluted EPS (TTM)

-11.39

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20257.2M7.5M8.1M0
20248.9M8.5M7.8M7.0M
20235.6M7.4M8.5M8.9M
2022169.0K640.0K1.9M3.7M
20210109.0K89.0K72.0K
2020000138.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Instil Bio, Inc.

TIL
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its lead product is ITIL-306, a Co-Stimulatory Antigen Receptor molecule to recognize folate receptor alpha, a tumor-associated antigen that is expressed on various solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
 CEO
 WEBSITEhttps://instilbio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES192

Instil Bio, Inc. Frequently Asked Questions

TIL is the stock ticker symbol of Instil Bio, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Instil Bio, Inc. is 56.02 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, TIL's PE ratio (Price to Earnings) is -0.75 and Price to Sales (PS) ratio is 6.93. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TIL PE ratio will change depending on the future growth rate expectations of investors.